AbbVie sponsors new ABBV-253 solid tumor trial; collaborates on epcoritamab lymphoma study
Two new trial registrations touch AbbVie this period, one as sponsor and one as a collaborator on an academic-led lymphoma study.
Two newly registered trials involve AbbVie in different capacities this period.
- A Phase 1 first-in-human trial of ABBV-253 in adults with advanced solid tumors is a study assessing adverse events, change in disease activity and pharmacokinetics of ABBV-2531, sponsored by AbbVie. The trial is expected to enroll approximately 130 participants at approximately 11 sites worldwide1 and is not yet recruiting.
- A Phase 2 trial testing epcoritamab combined with lenalidomide in relapsed or refractory large B-cell lymphoma after second-line CAR T-cell therapy is sponsored by the Lymphoma Academic Research Organisation, with AbbVie as a collaborator2. The study aims to enroll approximately 55 adults across multiple centers in France2 and is not yet recruiting, with its primary endpoint being overall response rate after Cycle 2, or at premature treatment discontinuation, according to the 2014 Lugano Response Criteria2.
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.